Shareholders greet shape-shifting Impro Precision’s fundraising with skepticism

The company is trying to shed its traditional industrial casting label to pivot toward high-end precision manufacturing, prompting investors to re-evaluate its worth

Key Takeaways:

• Impro Precision is raising HK$539 million through a share sale for capacity expansion and new process facilities at its plants in Mexico and China
• The company has been making inroads into the high-end medical market, with revenue from that business up over 50% last year

By Lee Shih Ta

Surging investments in AI data centers and high-end medical equipment are boosting global demand for precision components. That’s providing a big business opportunity for Impro Precision Industries Ltd. (1286.HK), which built its original business on investment casting and precision machining, but more recently has been moving into the aerospace, energy and medical fields. To assist that effort, the company has launched a relatively large share sale, earmarking the funds for capacity expansion and boosting its efforts at the higher end of the market.

Last week the company announced plans to sell up to 60 million new shares for HK$9.10 each, representing a discount of 13.6% to its closing price before a trading halt. The placement will raise approximately HK$539 million ($69 million), which will be used to expand capacity at its plants in Mexico and China, as well as for development of new processes and capacities. Some funds will also be used for debt repayment and working capital.

The company’s stock price has stalled since hitting a high of HK$11.80 in mid-May. After announcing the share sale, and steeply discounted placement price, the stock slumped more than 5% during the day, putting its near-term trajectory under pressure.

Founded nearly three decades ago in 1998, Impro Precision started out in component machining before expanding into investment casting, precision machining, and sand casting. The company’s core strength has been its capacity to manufacture high-precision and highly complex components. While these products may not capture investor imagination quite like AI chips, they present formidable technical thresholds and certification barriers in fields such as aero-engines, energy equipment and medical devices.

The company’s earlier focus on automotive and general industrial components led many to long view it as a traditional industrial manufacturing enterprise. But it’s rapidly shedding that image, banking on strong growth from higher-end sectors such as energy and medical that have notably outpaced its traditional automotive and general industrial segments.

One of the first things to catch investor attention was demand for energy equipment needed to power a boom in AI data center construction. That boom has created a concurrent jump in demand for power supplies and liquid cooling systems in North America, which has driven up the need for high-horsepower engines and energy equipment. That’s helped Impro Precision jump on the AI infrastructure wave, since its products are widely used in such equipment.

The company’s revenue from high horsepower engines jumped 29% year-over-year in the first quarter of 2026, while construction equipment revenue grew 33%, and recreational boat and vehicle revenue climbed 41.4%. Revenue from other categories related to liquid cooling systems within its diversified industrials segment saw an even sharper 81.4% surge. The company noted that strong demand for liquid cooling systems tied to AI data centers was a primary catalyst for growth of that category. Meanwhile, energy end-market revenue skyrocketed 89.5% year-over-year, reversing a downturn caused by a sluggish oil and gas market last year.

Medical equipment inroads

While the AI narrative sounds sexy, Impro Precision’s medical business is what’s truly leading investors to take a second look at the company. According to its 2025 annual report, the company’s medical end-market revenue soared 55.2% during the year, making it the year’s fastest-growing segment. Equally important, the segment’s client roster includes many of the world’s leading high-end medical equipment makers such as GE Healthcare, Stryker, Philips Healthcare and Leica Microsystems, as well as da Vinci Surgical System.

Getting into the supply chain for high-end medical equipment is no easy feat, creating big barriers to entry for companies eyeing the business. The process features lengthy certification cycles and requires high customer stickiness to make things worthwhile. Surgical robotic components are one area that demands exceptionally rigorous precision, resulting in prohibitive supplier switching costs. Impro Precision revealed in its latest annual report that it is continuously evaluating the possibility of a spinoff and independent listing for its related medical end-market businesses.

Fueled by a boom in precision manufacturing demand, the company achieved record revenue and profits last year. Its revenue expanded a further 22.5% to HK$1.43 billion in the first quarter of this year, and management raised its full-year revenue growth guidance from an initial mid-single-digit estimate to between 15% and 20%.

On the cash flow front, net cash from operating activities reached HK$1.26 billion last year, while net debt stood at HK$1.71 billion at year-end, equating to a net gearing ratio of roughly 30.4%. With ongoing investments in aerospace, medical and North American capacity expansion, the company continues to be in constant need of new cash.

Perhaps the most critical piece of its puzzle is the Mexican expansion. As Sino-U.S. tensions have mounted in recent years, Mexico has emerged as a crucial hub for the relocation of supply chains that were once based in China. Impro Precision is currently advancing the expansion of its San Luis Potosí campus in Mexico in hopes of establishing a more comprehensive localized manufacturing footprint in North America. But the company’s past disclosures show the Mexican plant remains in a capital-intensive investment and capacity ramp-up phase, putting short-term pressure on its profitability.

From a valuation perspective, the market has begun to gradually re-evaluate Impro Precision’s position. As that happens, the company’s rolling price-to-earnings (P/E) ratio has climbed to 25 times, higher than the 14 for auto parts maker Minth Group (0425.HK). Yet, framed against its growing position in high-end precision manufacturing and the medical device supply chain, such a valuation doesn’t seem particularly aggressive. By comparison, Chinese medical equipment maker iRay Technology (688301.SH) trades at a P/E of roughly 60 times, while Tuopu Group (601689.SH), an auto parts maker pivoting to robotics components, trades at 41 times — clearly indicating room for upside.

Investors may still be on the fence about whether to view Impro Precision as a traditional industrial casting firm or a high-end precision manufacturer. Growing demand for AI infrastructure and premium medical products, together with reconfiguring North American supply chains, are clearly driving new demand for the company’s products and services. Impro Precision’s ability to further scale those areas will ultimately determine where its valuation lands.

To subscribe to Bamboo Works weekly free newsletter, click here